Document:

EX-10.4.2

  Exhibit 10.4.2

 
  

 
 

	 
	 InMed Pharmaceuticals, Inc.
 Suite #340- 200 Granville St.

Vancouver, BC V6C 1S4
 Canada
  

 
  
  

 
  
  

01 SEPTEMBER 2018
  

 
 Dear Eric Hsu,

 
 In recognition of your agreement to increase your work commitment to InMed to 80% of
full time, I am pleased to make the following changes to your compensation:
  
 Base
Salary - will increase to $224,000 as of the date of this letter; and
  

Options - subject to approval by the Board of Directors, you will be issued an additional 270,000 options to purchase common shares in the Company as per the
Company’s standard options policies, priced on or around the date of this letter.
  

On behalf of the entire Management Team and Board of Directors, thank you for your contributions to the Company’s success and we look forward to achieving more,
together.
  
 /s/ Eric A. Adams

Eric A. Adams President and CEO
 InMed Pharmaceuticals Inc.EX-10.4.3

  Exhibit 10.4.3

 
 

	 
	 InMed Pharmaceuticals,
Inc.
 Suite #340- 200 Granville St. 
 Vancouver, BC V6C 1S4
 Canada

 

  

 
  
  

 
  
 4 March
2019
  
  
 Dear Eric
Hsu,
  
 On behalf of InMed’s Board
of Directors, I am pleased to announce your promotion to Senior Vice President, Pre-Clinical R&D. Additionally, in recognition of your agreement to increase your work commitment to InMed to full time (100%), I am pleased to make the following
changes to your compensation:
  
 Base Salary - will increase to $290,000 effective March 1,
2019; and
  
 Options - subject to approval by the Board of
Directors, you will be issued an additional 255,000 options to purchase common shares in the Company as per the Company’s standard options policies, priced on or around the date of this letter.

 
 On behalf of the entire Management Team and Board of Directors, thank you for your contributions to
the Company’s success and we look forward to achieving more, together.
 /s/ Eric A. Adams 

Eric A. Adams President and CEO
 InMed Pharmaceuticals
Inc.EX-10.5

   
  Exhibit 10.5
  

AMENDED AND RESTATED
 EXECUTIVE EMPLOYMENT AGREEMENT
  
 THIS
AGREEMENT made this 8th day of April, 2020 (the “Effective Date”)
  
 
BETWEEN:
  

INMED PHARMACEUTICALS INC., a company incorporated under the laws of British
Columbia (the “Company”), with offices at Suite 310, 815 West Hastings St., Vancouver, British Columbia V6C 1B4 Facsimile: (604) 683-2506

 

AND: 

 
 ALEXANDRA D. J. MANCINI (the “Executive”), of 5371 Kew Cliff Road, West Vancouver, British Columbia V7W 1M3

 

 WHEREAS:

 

A.          The Company is a clinical
stage biopharmaceutical company that specializes in developing therapies through the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems;

 

B.           The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and
  

C.           The Company and the
Executive entered into an executive employment agreement dated October 28, 2016, as amended, (the “Original Agreement”) for the performance of such services, and the parties now desire to amend and restate the Original Agreement
on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged.
  
 NOW
THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree as follows:

 

		1.	EMPLOYMENT

  

		(a)	The Executive will be employed by and will serve the Company as its Senior Vice President (SVP) of Clinical and Regulatory Affairs and will have
powers and duties consistent with such position as may from time to time be prescribed by the Chief Executive Officer (CEO) and Board of Directors of the Company (the “Board”), as outlined in Exhibit A. The Executive will report
directly to the CEO and will comply with all lawful instructions given by the CEO.

  

 

  

 -
2
 - 

  

		(b)	The terms and conditions of this Agreement will have effect as and from the Effective Date and the Executive’s employment as SVP will
continue until terminated as provided for in this Agreement.

  

		(c)	The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement, the Executive’s employment with the
Company is subject to and governed by the Company’s policies as established from time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions of the Agreement. The
Executive will inform herself of the details of such policies and amendments thereto established from time to time.

  

		(d)	The Executive will devote herself exclusively to the Company’s business and will not be employed or engaged in any capacity in any other
business without the prior permission of the CEO, such permission not to be unreasonably withheld. For greater certainty, the Executive will not serve in any capacity with any pharmaceutical or biotechnology company, firm, organization, enterprise,
association or other similar entity, without the prior permission of the CEO. Notwithstanding the foregoing, the Executive may manage her personal investments or engage in charitable or other community activities as long as those services and
activities do not interfere with the Executive’s performance of her duties to the Company.

  

		(e)	The parties acknowledge and agree that the Confidentiality and Assignment of Inventions Agreement executed by the parties dated October 28, 2016
in the form attached hereto as Exhibit B shall remain in full force and effect.

  

		2.	REMUNERATION AND BENEFITS

 

		(a)	Base Salary.

 

		(i)	The Company will pay the Executive an annual salary of $309,000, per annum, less required deductions (the “Base Salary”).

 

		(ii)	The Base Salary will be payable semi-monthly. The Executive’s Base Salary will be reviewed annually by the Board and the compensation
committee of the Company in accordance with the Company’s annual performance and compensation review process, including consideration of the Company’s market capitalization and financial stability, and is subject to increase but not
decrease, except for an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily result in an increase to the Base Salary. The base salary in effect at any given time is referred
to as “Base Salary” and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable in a manner that is consistent with the Company’s usual payroll practices for
senior executives.

  

 

  

 -
3
 - 

  

		(b)	Bonus. The Executive is eligible to be considered for an annual discretionary bonus of up to 35% of Base Salary (the “Target
Bonus”) which will be subject to the approval of the Board and the compensation committee of the Company, in their sole discretion, on an annual basis in accordance with the Company’s annual performance and compensation review
process, including consideration of the Company’s market capitalization and financial stability. Payment of a bonus in any one year will not indicate the payment of a bonus in any other year.

 

		(c)	Stock Options Issued with Original Agreement. The Executive’s allotment of stock options in the capital of the Company shall be
400,000 stock options (the “Options”) pursuant to the Company’s Incentive Stock Option Plan (the “Stock Option Plan”). If the Company has granted any stock options to the Executive prior to the Original
Agreement date, then the number of stock options so granted will be deducted from the number of Options to be issued to the Executive hereunder, so that the total number of stock options granted to the Executive is 400,000 stock options. The Options
shall be priced at Market price in accordance with and subject to the Option policies of the Canadian Securities Exchange and the Company’s Insider Trading Guidelines and the blackout provisions therein. The Options will vest as
follows:

 

	Type of
Option	Total Number of Options	Vesting Number	Vesting Date
	Options issued with Original Agreement	400,000
	100,000	28 October
2016
	100,000	6 months after

 28 October 2016
	100,000	12 months after

 28 October 2016
	100,000	18 months after

 28 October 2016

  

		(d)	The Options will cease to vest on the Date of Termination of this Agreement (as defined in Section 5(g)). The terms and conditions relating to the
Options will be subject to the Option Agreement that is entered into concurrently with the Original Agreement, as well as the Stock Option Plan. If there is any conflict between the terms of this Agreement and the Stock Option Plan, the terms of the
Stock Option Plan will govern. If there is any conflict between the terms of this Agreement and the Option Agreement, the terms of this Agreement will govern to the extent of the conflict.

 

		(e)	Expenses. The Company will reimburse the Executive for all reasonable expenses actually and properly incurred by the Executive in
performing services under this Agreement, in accordance with the policies and procedures then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting the Executive’s
claims for reimbursement.

  

 

  

 -
4
 - 

  

		(f)	Other Benefits. The Company will facilitate the Executive’s enrolment in the Company’s insurance benefits plans, if any, as may
be amended from time to time by the Company or the Company’s insurance carrier. In all cases, eligibility to participate in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable
insurance carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment of benefits under the benefits package will be governed by the terms of such documents and policies. The
Company will not be responsible for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to amend, change or terminate any of the insurance benefit plans or providers.

 

		(g)	Vacation. The Executive is entitled to paid holidays and vacation days each year, in an amount determined in accordance with and subject to
the Company’s applicable policies in effect, and as may be amended from time to time. The Executive will be entitled to 30 days of vacation per calendar year, which will be pro-rated for any year in which the Executive is only employed with
the Company for a portion of the year or for any period in which the Executive is not a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over of vacation days will be
according to Company policy, and any accrued but unused vacation days will be paid out upon termination or otherwise as per Company policies.

 

		3.	NON-COMPETITION AND NON-SOLICITATION

 

		(a)	The biotechnology industry is highly competitive and employees leaving the employ of the Company have the ability to cause significant damage to
the Company’s interests if they join a competing business immediately upon leaving the Company.

  
 (b)          Definitions:

 

(i)         
 “Business” or “Business of the Company” means the researching, developing, commercializing, producing and marketing novel, cannabinoid-based therapies combined with innovative drug delivery
systems.
  

(ii)         
“Competing Business” means any endeavor, activity or business which is competitive in any material way with the Business of the Company worldwide.

 

(iii)        
“Contact” means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator, strategic partner, licensee, contact or prospect of the Company (or of its
partners or funders) with whom the Executive dealt or otherwise became 
  
 
 

  

 -
5
 - 

 

 aware of during the term of the Executive’s employment in any
capacity with the Company.
  

		(iv)	“Restricted Period” means a period of 12 months.

 

(c)         
  Reasonableness. The Executive hereby acknowledges and agrees that:
  

		(i)	both before and since the commencement of the Executive’s employment by the Company, the Company has operated and competed and will operate
and compete worldwide, with respect to the Business of the Company;

  

		(ii)	competitors of the Company and the Business are located worldwide;

 

		(iii)	in order to protect the Company adequately, any enjoinder of competition would have to apply to any country in which the Company, during the term
of the Executive’s employment, had material business relationships;

  

		(iv)	during the course of the Executive’s employment with the Company, on behalf of the Company, the Executive will acquire knowledge of, and
will come into contact with, initiate and establish relationships with, both existing and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive may become the senior or
sole representative of the Company dealing with such persons; and

  

		(v)	in light of the foregoing, the provisions of this Article 3 are reasonable and necessary for the proper protection of the Business of the
Company.

  

		(d)	Restrictive Covenant. Except as set forth on Exhibit D attached hereto, during the term of the Executive’s employment and for the
Restricted Period after the termination thereof, the Executive shall not, without the prior written consent of the Board, such consent to be granted or withheld in the Board’s sole discretion, within the geographic scope of any country in
which the Company, during the term of the Executive’s employment, had material business relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially involved in a Competing
Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.

  

		(e)	Exception. The Executive shall not be in default of Section 3(d) by virtue of the Executive:

 

		(i)	following the termination of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five percent (5%) of the
issued and outstanding shares of, or any other interest in, any corporation or other entity which is listed on any recognized stock exchange, that is a Competing Business; or

 

 

		(ii)	during the term of the Executive’s employment, holding, strictly for portfolio purposes and as a passive investor, issued and outstanding
shares 

  

 

  

 -
6
 - 

  

of, or any other interest in, any corporation or other entity, the
business of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business, and provided further that the Executive first obtains the Company’s written consent, which consent will
not be unreasonably withheld.
  

If the Executive holds issued and outstanding shares or any other interest in a
corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose of the
Executive’s shares or other interest in such corporation or other entity.
  

		(f)	Non-Solicitation. The Executive shall not, during the term of the Executive’s employment and for the Restricted Period after the termination thereof for any
reason, whether legal or illegal, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever,
without the prior written and informed consent of the Company, directly or indirectly:

  

		(i)	canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business of) any Contact, or otherwise solicit,
induce or encourage any Contact to curtail or cease its relationship with the Company, for any purpose which is competitive with the Business; or

 

		(ii)	accept (or procure or assist the acceptance of) any business from any Contact which business is competitive with the Business;
or

  

		(iii)	be employed by or supply (or procure or assist the supply of) any goods or services to any Contact for any purpose which is competitive with the
Business; or

  

		(iv)	employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit, induce or
encourage to leave the employment or engagement of the Company, any individual who is employed or engaged by the Company whether or not such individual would commit any breach of the Executive’s contract or terms of employment or engagement by
leaving the employ or the engagement of the Company, provided that the Executive shall be permitted, solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.

 

		(g)	Validity. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive’s activities following the termination
of the Executive’s employment with the Company be restricted in the manner described in this Article 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions. The Executive
agrees that should any of the restrictions contained in this Article 3 be found to be unreasonable to any extent by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction, the
area of the restriction

  

 

  

 -
7
 - 

 

or the duration of the restriction, then such restriction shall be reduced to that
which is in fact declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order to ensure that the intention of the parties is given the greatest possible effect.

 

		4.	INJUNCTIVE RELIEF

 

		(a)	The Executive understands and agrees that the Company has a material interest in preserving the relationships it has developed with its
executives, customers and suppliers against impairment by competitive activities of a former executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Article 3 are reasonably required for the protection of the
Company and its goodwill and that the Executive’s agreement to those restrictions and covenants by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to enter into this
Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an inducement.

 

		(b)	The Executive understands and acknowledges that if the Executive breaches Article 3, that breach will give rise to irreparable injury to the
Company for which damages are an inadequate remedy, and the Company may pursue injunctive relief for such breach in a court of competent jurisdiction.

 

		5.	TERMINATION

  
 The
Executive’s employment by the Company may be terminated under the following circumstances:
  

		(a)	Death. The Executive’s employment hereunder will terminate upon the Executive’s death.

 

		(b)	Disability. The Company may terminate the Executive’s employment if the Executive is disabled (as determined by the CEO) in a manner
that renders the Executive unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of six (6) months or more. Nothing in this
Section 5(b) will be construed to waive the Executive’s rights, if any, under the Company’s insurance benefits plans accruing prior to termination or under applicable law.

 

		(c)	Termination by Company for Cause.

 

		(i)	The Company may terminate the Executive’s employment For Cause at any time, without notice or payment in lieu thereof. The payment by the
Company of the Executive’s Accrued Benefits shall be subject to any other rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.

 

 

  

 -
8
 - 

  

		(ii)	For the purposes of this Agreement, “For Cause” shall mean:

 

		(A)	the Executive is convicted of a crime involving dishonesty, breach of trust, or physical harm to any person (excluding driving while affected by
drugs or alcohol) or any violation of provincial or federal securities laws;

  

		(B)	the Executive willfully engages in conduct that is in bad faith and materially injurious to the Company, monetarily or otherwise, including but
not limited to, misappropriation of trade secrets, fraud or embezzlement;

  

		(C)	the Executive commits a material breach of this Agreement;

 

		(D)	the Executive willfully refuses to implement or follow a lawful policy or directive of the Company; or

 

		(E)	the Executive willfully and on a continuing basis fails to perform her duties hereunder diligently and professionally.

 

		(d)	Termination by the Company without Cause.

 

		(i)	The Company, in its sole discretion, may terminate the Executive’s employment under this Agreement without Cause at any
time.

  

		(ii)	For the purposes of this Agreement, any termination by the Company of the Executive’s employment under this Agreement that does not
constitute a termination “For Cause” under Section 5(c) and does not result from the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination “without
Cause”.

  

		(e)	Resignation by Executive.

 

		(i)	The Executive may terminate her employment by providing to the Company Notice of Termination of her employment at least 90 days prior to the
effective date of resignation. During such notice period Executive shall continue to diligently perform all of Executive’s duties hereunder, provided that the Company shall have the option, in its sole discretion, to waive such notice period,
in whole or in part, and if it does so, the Executive’s resignation will become effective and the Executive’s employment will cease on the date set by the Company in the notice of waiver, and the Executive shall be entitled to her
Accrued Benefits up to and including the Date of Termination (as defined in Section 5(g)(iii)). In the event the Company waives the Executive’s notice hereunder, the Company, in its sole discretion, in the circumstances, may pay the Base
Salary portion of the Executive’s Accrued Benefits by way of one or more lump sum payments, by way of salary continuance or by a combination of both.

 

		(ii)	The Executive may terminate her employment for Good Reason within 12 months following a Change in Control of the Company in accordance with,
and subject to, the process set out in Section 7(c).

  

 

  

 -
9
 - 

  

		(f)	Notice of Termination. Except for termination as specified in Section 5(a), any termination of the Executive’s employment by the
Company or any termination of the Executive’s employment by the Executive must be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, “Notice of Termination” means a written
notice that indicates the specific termination provision in this Agreement upon which the termination is based.

  

		(g)	Date of Termination. For the purposes of this Agreement, “Date of Termination” means:

 

		(i)	if the Executive’s employment is terminated by her death, the date of her death;

 

		(ii)	if the Executive’s employment is terminated on account of disability under Section 5(b) or by the Company for Cause under Section 5(c), or
by the Company without Cause under Section 5(d) on the date the Notice of Termination is given;

  

		(iii)	if the Executive terminates her employment under Section 5(e)(i) without Good Reason, on the effective date of resignation specified by the
Executive in the Notice of Termination (which shall be at least three (3) months after the date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is 90 days after the date of the
Notice of Termination; and

 

		(iv)	if the Executive terminates her employment under Section 5(e)(ii) for Good Reason following a Change in Control of the Company, the date on which
a Notice of Termination.

  

Notwithstanding the foregoing, if the Executive gives a Notice of Termination to
the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.

 

		6.	COMPENSATION UPON TERMINATION

 

		(a)	Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide
to the Executive (or to her authorized representative or estate) on or before the time required by law, but in no event more than 30 days after the Executive’s Date of Termination:

 

		(i)	unpaid expense reimbursements;

 

		(ii)	accrued but unused vacation to the extent payment is required by law or Company policy;

 

		(iii)	any vested benefits the Executive may have under any employee benefit plan of the Company;

 

 

  

 -
10
 - 

  

		(iv)	any earned but unpaid Base Salary; and

 

		(v)	any earned but unpaid annual bonus for the prior fiscal year;

 

for service up to and including the Date of Termination (collectively the
“Accrued Benefits”). The Executive shall not be entitled to any other salary, compensation, bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided hereunder, under the
Company’s employee benefit plans or as expressly required by applicable law.
  

		(b)	Termination by the Company without Cause. If the Executive’s employment is terminated by the Company without Cause, then the Company
shall pay the Executive her Accrued Benefits as of the Date of Termination. In addition, subject to Article 7 and the Executive providing the Company with a general release of claims in a form and manner that includes but is not limited to the terms
set forth in the attached Exhibit C (the “Release”) within the 60-day period following the Date of Termination, the Company shall pay the Executive an amount (the “Severance Amount”) calculated as
follows:

  

		(i)	if terminated during the initial 12 months of employment, an amount equal to four (4) months’ Base Salary, less
withholding;

  

		(ii)	if terminated any time after the initial 12 months of employment but prior to the 36 month anniversary of the Original Agreement date, an amount equal to eight (8)
months’ Base Salary, less withholding; or

  

		(iii)	if terminated any time after the 36 month anniversary of the Original Agreement date, an amount equal to twelve (12) months’ Base Salary,
less withholding;

  

plus:

 

		(iv)	additionally, in any event, a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive from the previous
three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to and including the Date of Termination.

 

The Company shall pay the Severance Amount within 60 days after the Date of
Termination, provided that if that 60-day period extends over two (2) calendar years, the Company shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay the
Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance Amount is inclusive of any entitlement to minimum standard severance under the British Columbia Employment Standards
Act.
  

 

  

 -
11
 - 

  

		7.	CHANGE IN CONTROL

 

		(a)	The provisions of this Article 7 set forth the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company.
These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to her assigned duties and her objectivity during the pendency and after the occurrence of any Change in Control. Where the
provisions of this Article 7 apply, they shall supersede the payment of the Severance Amount under Section 6(b). The provisions of this Article 7 are subject to the Executive providing to the Company, and not revoking, a fully effective
Release.

  

		(b)	Definitions. For purposes of this Agreement:

 

		(i)	“Change in Control” means the consummation of any of the following:

 

		(A)	the sale of all or substantially all of the assets of the Company to an unrelated person or entity;

 

		(B)	a merger, reorganization, or consolidation involving the Company in which the shares of voting stock outstanding immediately prior to the
transaction represent or are converted into or exchanged for securities of the surviving or resulting entity that, immediately upon completion of the transaction, represent less than 51% of the outstanding voting power of the surviving or resulting
entity;

  

		(C)	the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transactions by
a person or group of persons; or

 

		(D)	any other acquisition of the business of the Company, as determined by the Board;

 

but any public offering by the Company, or another capital raising event, or a
merger effected solely to change the Company’s domicile does not constitute a Change in Control; and
  

		(ii)	“Good Reason” shall mean the occurrence of any of the following events without the Executive's prior written
consent:

  

		(A)	a change in the Executive’s position which materially reduces the Executive’s responsibilities from the responsibilities in effect
immediately prior to the Change of Control;

 

		(B)	a reduction by the Company of the Executive’s Base Salary or Target Bonus percentage, except for an across-the-board salary reduction
affecting all senior executives of the Company; or

  

		(C)	a relocation of Executive’s principal place of employment by more than 30 kilometres.

 

		(c)	Change in Control Severance. If within 12 months following a Change in Control:

 

 

  

 -
12
 - 

  

		(i)	the Company terminates the Executive’s employment with the Company without Cause; or

 

		(ii)	the Executive resigns from her employment with the Company for Good Reason;

 

then,

 

		(iii)	in addition to paying the Executive her Accrued Benefits and in lieu of paying the Executive the Severance Amount, the Company shall pay to the
Executive an amount (the “Change in Control Severance Amount”) as follows:

  

		(A)	an amount equal to twelve (12) months’ Base Salary, less withholding;

 

plus:

 

		(B)	a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive from the previous three (3) calendar years
preceding the Date of Termination, pro-rated for the then current calendar year up to and including the Date of Termination.

 

The Company shall pay the Change in Control Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two (2) calendar years, the Company shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the
circumstances, may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum
standard severance under the British Columbia Employment Standards Act; and
  

		(iv)	notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other
stock-based awards held by the Executive shall immediately accelerate, vest, and become fully exercisable or non-forfeitable as of the Date of Termination hereunder.

 

		8.	RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT

 

The Executive will return to the Company all Company documents, files, manuals,
books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to Company upon the termination of the Executive’s employment with the Company for any reason.

 

 

  

 -
13
 - 

  

		9.	GENERAL PROVISIONS

 

		(a)	Withholding. All payments made by the Company to the Executive under this Agreement will be net of any tax or other amounts required to be
withheld by the Company under applicable law. Nothing in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that minimizes tax consequences for the
Executive.

  

		(b)	Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, or
otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of
the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this Agreement.

 

		(c)	Successor to the Executive. This Agreement inures to the benefit of and is enforceable by the Executive’s personal representatives,
executors, administrators, heirs, distributees, devisees, and legatees. If the Executive dies after her termination of employment but prior to the completion by the Company of all payments due the Executive under this Agreement, the Company shall
continue the payments to the Executive’s beneficiary designated in writing to the Company prior to her death (or to her estate, if the Executive fails to make such a designation).

 

		(d)	Non-Waiver. Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the
other party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.

 

		(e)	Severability. In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in
part, the remaining provisions, or parts thereof, will be and remain in full force and effect.

  

		(f)	Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the employment of the
Executive and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each of the parties releases
and forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect of any agreement.

 

		(g)	Survival. The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive’s
employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.

  

 

  

 -
14
 - 

  

		(h)	Modification of Agreement. Any modification of this Agreement must be in writing and signed by both the Company and the Executive or
it will have no effect and will be void.

 

		(i)	Disputes. Except for disputes arising in respect of Article 3, all disputes arising out of or in connection with this Agreement and
the employment relationship between the parties, are to be referred to and finally resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules. The place of arbitration will be
Vancouver, British Columbia.

 

		(j)	Governing Law. This Agreement will be governed by and construed according to the laws of the Province of British Columbia,
Canada.

  

		(k)	Notices. Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing and delivered
in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the
case of the Company, at its main offices, attention to the Corporate Secretary.

  

		(l)	Independent Legal Advice. The Executive agrees that she has obtained or has had an opportunity to obtain independent legal advice in
connection with this Agreement, and further acknowledge that she has read, understands, and agrees to be bound by all of the terms and conditions contained herein. The Executive further agrees that the consideration described aforesaid is accepted
voluntarily for the purpose of employment with the Company under the terms and conditions described above.

  

		(m)	Counterparts. This Agreement may be executed in any number of counterparts, and by each party on separate counterparts, each of which
counterparts, when so executed and delivered is to be taken to be an original; but those counterparts 

  

 

  

 -
15
 - 

  

together constitute one and the same document. PDF, facsimile,
scanned, and electronic signatures have the same legal effect as original ink signatures.
  
 IN WITNESS WHEREOF this
Agreement has been executed by the parties hereto as of the date and year first above written.
  
 

	 	)	 
	SIGNED, SEALED AND DELIVERED	)	 
	by ALEXANDRA D.J. MANCINI in the	)	 
	presence of:	)	 
	 	 	 
	 	 	 
	Witness Signature	)	ALEXANDRA D.J. MANCINI, M.Sc.
	 	)	 
	Witness Name	)	 
	 	)	 
	Witness Address	)	 
	 	)	 
	 	)	 
	 	)	 
	Witness Occupation	)	 

  

	INMED PHARMACEUTICALS INC.	 
	 	 	 
	Per:	 	 
	 	Eric A. Adams	 
	 	President and CEO	 

  
 

  

 

  

EXHIBIT A

 

 

 

ROLE AND RESPONSIBILITIES
 SENIOR VICE PRESIDENT, CLINICAL AND
REGULATORY AFFAIRS
  

 The Sr.
Vice President of Clinical & Regulatory Affairs is accountable to the CEO for strategy and operational excellence related to InMed’s clinical research programs, global regulatory compliance and submissions and quality assurance operations.
Leads Sr. Management team in the development and evaluation of strategies to ensure InMed’s continued growth and business success. Leads, develops and mentors reporting staff and departments in Clinical Research, Medical Affairs, Clinical Data
Management, Regulatory Affairs and Quality Assurance. Has financial accountability for the programs under her supervision.
  

Essential Duties and Responsibilities:
  

		1	Executive Management

 

		●	Serve as a key and active member of the Senior Management Team, interacting with the team to ensure business objectives are aligned and that the company is performing to operational objectives. Participate in the preparation and on-going
evaluation of the company’s strategic and operational plan.

 

		●	Coach and mentor the Regulatory and Clinical organization ensuring appropriate levels of accountability for decision making and clearly communicate cross functionally within the organization.

		●	Maintains up to date knowledge of overall business processes and company strategies and operationally plans and processes in finance planning and reporting, HR planning, project planning, management and reporting.

 

		2	Regulatory Affairs

 

		●	Provide management and leadership to the Regulatory Affairs organization in the development and implementation of regulatory strategies and processes to gain product approvals worldwide.

		●	Provide counsel, training and interpretation of FDA and other regulatory requirements to all company personnel.

 

		●	Oversee preparation and filing of all regulatory documents with the FDA and international regulatory agencies.

 

		●	Develop and maintain external relationships with key opinion leaders, medical directors and regulatory officials.

 

		●	Direct the development of systems, practices and processes to ensure effective ongoing review of drug development program design and adverse events.

		●	Provide leadership and direction for significant deviation events that may impact compliance status or significant business risk.

 

		3	Clinical Affairs

 

		●	Develop & successfully execute global clinical and regulatory strategies and implementation plans to ensure product approval and adoption while meeting corporate objectives within applicable regulations and guidelines.

		●	Direct the development of systems, practices and processes to ensure efficient and effective clinical trials including clinical trial management, data analysis, final study report and publication while ensuring all clinical studies operate to
the highest ethical and safety standards.

 

		●	Keep abreast of competitive regulatory and clinical practices and utilize this knowledge during the ongoing development and adjustment of the company plans.

 
 
 

  

 

  

		●	Develop and maintain strong internal and external relationships with regulatory bodies and medical/clinical professionals to ensure effective clinical projects are in place and completed to support the company product and technology
objectives.

  
 Qualifications:

		1	Education & Experience:

 

		●	MSc degree in life sciences, engineering or business

 

		●	15+ years regulatory and clinical experience in a life sciences technology driven company.

 

		●	Experience in strategic planning and collaboration with executive and key operational groups.

 

		●	Progressive & proven record of leadership and managing regulatory/clinical organization’s with global responsibility and establishing long term strategic growth initiatives.

		●	Experience with all phases of the product development lifecycle, including concept, design, implementation, verification and validation activities necessary for product commercialization.

		●	Extensive experience in cGMP and other Regulatory compliance requirements. Experienced in regulatory filings for US, Canada and other key countries/regions.

 

		2	Required Knowledge, Skills & Abilities:

		●	High level of personal and professional integrity and trustworthiness with strong work ethic and the ability to work independently with minimal direction.

		●	Excellent communications and presentation skills.

 

		●	Ability to develop and manage a high performance team focused on accountability and meeting and exceeding expectations.

 

		●	Ability to lead, influence, create and work within cross-functional team environments.

 

		●	Assertive, take-charge, proven manager with a strong results orientation, positive “can do” attitude and a sense of urgency to get things done.

  
 
 

  

 

  
  
  

EXHIBIT B

 

CONFIDENTIALITY
 AND ASSIGNMENT OF INVENTIONS AGREEMENT

 

THIS AGREEMENT (this “Agreement”) dated for reference the __th day of
October, 2016 (the “Effective Date”).
  

 BETWEEN:

 

INMED PHARMACEUTICALS INC., a company incorporated under the laws of British
Columbia (the “Company”), with offices at Suite 350, 409 Granville St, Vancouver, B.C. V6C 1T2
 Facsimile: (604) 683-2506
  
  AND:

 

Alexandra D.J. Mancini (the “Executive”), of 5371 Kew Cliff
Road, West Vancouver, BC, V7W 1M3.
  

WHEREAS:

 

A.       The Company is a pre-clinical stage
biopharmaceutical company that specializes in developing therapies through the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems;

 

B.       In connection with the employment of the
Executive by the Company, the parties desire to establish the terms and conditions under which the Executive will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information confidential,
to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed or
disclosed by the Executive over the course of her work during her employment with the Company, as set out in this Agreement.
  
 NOW
THEREFORE THIS AGREEMENT WITNESSES that in consideration of the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows:

 

		1.	INTERPRETATION

 

		1.1	Definitions. In this Agreement:

  

		(a)	“Affiliate” means, in respect of the Company, a company or other entity which
directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of this definition, “control” means direct or indirect beneficial ownership of a greater than 50% interest in the
income of such company or entity or such other relationship as, in fact, constitutes actual control.

  
 

  

2
 

  
 
		(b)	“Business” or “Business of the Company”
means:

  

		(i)	researching, developing, commercializing, producing and marketing novel, cannabinoid-based therapies
combined with innovative drug delivery systems; or

 

		(ii)	any other area in which the Company has an active research and development program on the date the
Executive’s employment with the Company terminates and in connection with which the Executive directly provided service or had direct supervisory responsibilities.

 

		(c)	“Confidential Information” shall mean all information, knowledge, or data, whether in
written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who
are not bound by obligations of confidentiality and:

 

		(i)	from which the Company or its Affiliates derive economic value, actual or potential, from the
information not being generally known; or

  

		(ii)	in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;

  

and which, without limiting the generality of the foregoing, shall
include:
  

		(iii)	all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs and delivery technology), other scientific strategies and concepts, designs, know-how, information, material,
formulas, processes, research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;

 

		(iv)	all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and commercial information and strategies, customer lists, compilations, agreements and contractual records and
correspondence; programs, devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally known and items provided or disclosed to the Company or its Affiliates by third parties
subject to restrictions on use or disclosure;

 

		(v)	all know-how relating to the Business of the Company, including all biological, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information, and all applications, registrations, licenses, 

 
 
 

  

3
 

  
 
	 	 	authorizations, approvals and correspondence submitted to regulatory authorities;

 

		(vi)	all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors’ research and development, intellectual property, operations, financial, clinical, regulatory, marketing, advertising and commercial strategies, that is not generally known;

 

		(vii)	all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and

  

		(viii)	all information relating to the Executive’s compensation and benefits, including her salary,
vacation, stock options, perquisites, severance notice, rights on termination and all other compensation and benefits, except that she shall be entitled to disclose such information to her bankers, advisors, agents, consultants and other third
parties who have a duty of confidence to the Executive and who have a need to know such information in order to provide advice, products or services to him.

 

All Work Product shall be deemed to be the Company’s Confidential
Information.
  

		(d)	“Intellectual Property” is used in its broadest sense and means and includes any
statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and to any Inventions, including, without limitation, rights and interests in and to the following:

 

		(i)	knowledge, know-how and its embodiments, including trade secret information;

 

		(ii)	patents in inventions, and all applications therefor;

 

		(iii)	copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works of
authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs, source code and object code, and all applications therefor;

 

		(iv)	trademarks, service marks, tradenames, business names and domain names and all applications
therefor;

  

		(v)	industrial designs and all other industrial or intellectual property and all applications therefor;
and

  

		(vi)	all goodwill connected with the foregoing.

 

		(e)	“Inventions” shall mean any and all inventions, discoveries, developments,
enhancements, improvements, concepts, formulas, designs, processes, ideas, 

  
 
 

  

4
 

  
 
	 	 	writings and other works, whether or not reduced to practice, and whether or not protectable under patent, copyright, trade secret or similar laws.

 

		(f)	“Work Product” shall mean any and all Inventions and possible Inventions relating to
the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during her involvement in any capacity with the Company, whether during or outside her regular working hours, except those Inventions made or
conceived by the Executive entirely on her own time that do not relate to the Business of the Company and do not derive from any equipment, supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or
through her involvement in any capacity with the Company.

 

		2.	CONFIDENTIALITY

 

2.1           
             Prior Business Confidential Information. The Executive represents and warrants to the Company that the Executive has not brought or used, and the Executive covenants
and agrees that the Executive will not use or bring to the Company any confidential information of any kind whatsoever of any prior party (the “Prior Business”) with whom the Executive was previously involved, whether such
involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the “Prior
Involvement”). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has
advised the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the
Company may suffer as a result of any breach by the Executive of her obligations to such Prior Business in that regard.
  
 2.2                        Basic Obligation of
Confidentiality. The Executive hereby acknowledges and agrees that in the course of her involvement with the Company, the Company may disclose to her or she may otherwise have access or be exposed to Confidential Information. The Company hereby
agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential Information on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive will
keep strictly confidential all Confidential Information and all other information belonging to the Company that she acquires, observes or is informed of, directly or indirectly, in connection with her involvement, in any capacity, with the Company
both during and after the term of her employment in any capacity with the Company.
  
 2.3                        Fiduciary Capacity. The
Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential Information.
  
 2.4                        Non-disclosure. Except with
the prior written consent of the Company, the Executive will not at any time, either during or after she involvement in any capacity with the Company;

 
 

  

5
 

  
 
		(a)	use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of her duties for the benefit of the Company and its Affiliates;

  

		(b)	publish or disclose any Confidential Information or recollections thereof to any person other than to
employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their duties for the Company or its Affiliates;

 

		(c)	permit or cause any Confidential Information to be used, copied, published, disclosed, translated or
adapted except as otherwise expressly permitted by this Agreement; or

  

		(d)	permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance with written procedures of the Company, as amended from time to time in writing.

 

2.5           
             Taking Precautions. The Executive will take all reasonable precautions necessary or prudent to prevent material in her possession or control that contains or refers
to Confidential Information from being discovered, used or copied by third parties.
  
 2.6                        The Company’s Ownership
of Confidential Information. As between the Executive and the Company, the Company shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.

 

2.7           
             Control of Confidential Information and Return of Information. All physical materials produced or prepared by the Executive containing Confidential Information,
including, without limitation, records, devices, computer files, data, notes, reports, proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates and all other materials prepared
in the course of her responsibilities to or for the benefit of the Company or its Affiliates, together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn over to the
Company’s possession every original and copy of any and all such items in her possession or control upon request by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.
  
 2.8                        Purpose of Use. The
Executive agrees that she will use Confidential Information only for purposes authorized or directed by the Company.
  
 2.9                        Exemptions. The obligations
of confidentiality set out in this Article 2 will not apply to any of the following:
  

		(a)	information that is already known to the Executive, though not due to a prior disclosure by the Company
or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or its Affiliates;

 
 

  

6
 

  
 
		(b)	information disclosed to the Executive by another person who is not obliged to maintain the
confidentiality of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;

 

		(c)	information that is developed by the Executive independently of Confidential Information received from
the Company or its Affiliates and such independent development can be documented by the Executive;

  

		(d)	other particular information or material which the Company expressly exempts by written instrument
signed by the Company;

  

		(e)	information or material that is in the public domain through no fault of the Executive;
and

  

		(f)	information required by operation of law, court order or government agency to be disclosed, provided
that:

  

		(i)	in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this
Agreement;

  

		(ii)	if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;

  

		(iii)	if the Company does not agree that the disclosure is required by law, this Agreement will continue to
apply, except to the extent that a Court of competent jurisdiction orders otherwise; and

  

		(iv)	if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable efforts to obtain confidential treatment of such Confidential Information.

 

		3.	ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS

 

3.1           
             Notice of Invention. The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable, throughout the course of her
involvement, in any capacity, with the Company and from which there is a reasonable basis to believe that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On her ceasing to be
employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company all Work Product.
  
 3.2                        Assignment of Rights.
Subject only to the exceptions set out in Attachment 1 attached to this Agreement, the Executive will assign, and does hereby assign, to the Company or,

 
 

  

7
 

  
 
at the option of the Company and upon notice from the Company, to the Company’s
designee, all of her right, title and interest in and to all Work Product, including all Intellectual Property rights therein. To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests,
the Executive hereby declares and confirms that such legal title is and will be held by the Executive only as trustee and agent for the Company or the Company’s designee. The Executive agrees that the Company’s rights hereunder shall
attach to all Intellectual Property rights in her Work Product, notwithstanding that it may be perfected or reduced to specific form after she has terminated her relationship with the Company. The Executive further agrees that the Company’s
rights hereunder are worldwide rights and are not limited to Canada, but shall extend to every country of the world.
  
 3.3                        Moral Rights. Without
limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the Copyright Act (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in other applicable
jurisdictions or at common law that she may have with respect to all Work Product, and agrees never to assert any moral rights which she may have in the Work Product, including, without limitation, the right to the integrity of the Work Product, the
right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product in any
context and in connection with any product, service, cause or institution, and the Executive further confirms that the Company may use or alter any Work Product as the Company sees fits in its absolute discretion.

 

3.4           
             Goodwill. The Executive hereby agrees that all goodwill she has established or may establish with clients, customers, suppliers, principals, shareholders, investors,
collaborators, strategic partners, licensees, contacts or prospects of the Company relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date, shall, as between the Executive
and the Company, be and remain the property of the Company exclusively, for the Company to use, alter, vary, adapt and exploit as the Company shall determine in its discretion.

 

3.5           
              Assistance. The Executive hereby agrees to reasonably assist the Company, at the Company’s request and expense, in:

 

		(a)	making patent applications for all Work Product, including instructions to lawyers and/or patent agents
as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification, to execute all formal documentation incidental to an application for letters patent and to execute assignment documents
in favour of the Company for such applications;

 

		(b)	making applications for all other forms of Intellectual Property registration relating to all Work
Product;

  

		(c)	prosecuting and maintaining the patent applications and other Intellectual Property relating to all Work
Product; and

  
 

  

8
 

  
 
		(d)	registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.

  

If the Company is unable for any reason to secure the Executive’s signature with
respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company and
its duly authorized officers and agents as her agent and attorney-in-fact, to act for and in her behalf and stead to execute and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal
force and effect as if executed by him.
  

3.6       
                Assistance with Proceedings. The Executive further agrees to reasonably assist the Company, at the Company’s request and expense, in
connection with any defence to an allegation of infringement of another person’s intellectual property rights, claim of invalidity of another person’s intellectual property rights, opposition to, or intervention regarding, an application
for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for registration thereof.

 

3.7       
                Commercialization. The Executive understands that the decision whether or not to commercialize or market any Work Product is within the
Company’s sole discretion and for the Company’s sole benefit and that no royalty or other consideration will be due or payable to him as a result of the Company’s efforts to commercialize or market any such Work Product.

 

3.8       
                Prior Business Intellectual Property. The Executive represents and warrants to the Company that she has not brought or used, and the Executive
covenants and agrees that she will not use or bring to the Company any Intellectual Property of any kind whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned by the Executive.
The Company and the Executive acknowledge and agree that the Company is not employing the Executive to obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised the Executive to comply
with any legal obligations the Executive may have to such Prior Business. The Executive covenants and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as a result any breach
by the Executive of her obligations to such Prior Business in that regard.
  
 3.9                        Prior Inventions. In order to
have them excluded from this Agreement, the Executive has set forth on Attachment 1 attached to this Agreement a complete list of all Inventions for which a patent application has not yet been filed that she has, alone or jointly with others,
conceived, developed or reduced to practice prior to the execution of this Agreement to which she has any right, title or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.
  
 
 

  

9
 

  
 
		4.	General

 

4.1       
                Term. Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive is no longer
working at or for the Company in any capacity.

 

4.2       
                No Conflicting Obligations. The Executive hereby represents and warrants that she has no agreements with or obligations to any other person with
respect to the matters covered by this Agreement or concerning the Confidential Information that are in conflict with anything in this Agreement, except as disclosed in Attachment 1 attached to this Agreement.

 

4.3       
                Publicity. The Executive shall not, without the prior written consent of the Company, make or give any public announcements, press releases or
statements to the public or the press regarding any Work Product or any Confidential Information.
  
 4.4                        Further Assurances. The parties
will execute and deliver to each other such further instruments and assurances and do such further acts as may be required to give effect to this Agreement.

 

4.5       
                Notices. All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand delivered or
sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to have
been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either party may change its address or its facsimile number by giving the other party written notice, delivered in accordance
with this section.
  

4.6       
                Equitable Remedies. The Executive understands and acknowledges that if she breaches any of her obligations under this Agreement, that breach may
give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company will be entitled
as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.

 

4.7       
                Non-Waiver. Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other party in
default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.

 

4.8       
                Severability. In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.
  
 4.9                        Entire Agreement. This Agreement
constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral, express or implied, including any
relating to the nature of the position or its duration, and each of the parties releases
  
 

  

10
 

  
 
and forever discharges the other of and from all manner of actions, causes of action, claim
or demands whatsoever under or in respect of any agreement.

 

4.10       
              Survival. Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article 2 (including the obligations of
confidentiality and to return Confidential Information, which shall endure, with respect to each item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections 3.2, 3.3, 3.4, 3.5, 3.6
and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.
  
 4.11                      Modification of Agreement. Any modification
of this Agreement must be in writing and signed by both the Company and the Executive or it will have no effect and will be void.
  
 4.12                      Governing Law. This Agreement will be
governed by and construed according to the laws of the Province of British Columbia, Canada.
  
 4.13                      Independent Legal Advice. The Executive agrees
that she has obtained or has had an opportunity to obtain independent legal advice in connection with this Agreement, and further acknowledge that she has read, understands, and agrees to be bound by all of the terms and conditions contained
herein.
  

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

 
 

  

11
 

  
  IN WITNESS WHEREOF this Agreement has been executed by the parties hereto as of the date and year first above written.

 

	
 SIGNED, SEALED AND DELIVERED by Alexandra DJ Mancini in
the presence of:	)

)

)

)

	 
	Witness Signature	)

)

	Alexandra DJ Mancini, MSc
	Witness Name	)

)

	 
	Witness Address	) 

 ) 
 
	 
	 	) 

 ) 
 
	 
	Witness Occupation	)	 

  

INMED PHARMACEUTICALS INC.

 
  

	Per:	 	 
	 	Eric A. Adams	 
	 	President and CEO	 

 
  
 

  

12
 

  
 
Attachment 1
 to Confidentiality and Assignment of Inventions
Agreement
  

EXCLUSIONS FROM WORK PRODUCT

 

NIL

 
 

  

 

  
 
EXHIBIT C

 

GENERAL RELEASE LANGUAGE

 

The Executive agrees, for and in consideration of the terms set out in the letter to which
this release is attached, and other good and valuable consideration (the receipt and sufficiency of which I hereby acknowledge) agrees for herself , her spouse, heirs, executor or administrator, assigns, insurers, attorneys, and other persons or
entities acting or purporting to act on her behalf (the “Executive’s Parties”), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries, directors, officers,
employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys, benefit plans sponsored by the Company, and said plans’ fiduciaries, agents and trustees (the “Company’s
Parties”), from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments, levies, and executions of any kind, whether in law or in equity, known or unknown, which the
Executive’s Parties have, have had, or may in the future claim to have against the Company’s Parties by reason of, arising out of, related to, or resulting from the Executive’s employment with the Company or the termination of that
employment. This release specifically includes without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of contract, any claim arising under federal, state or local law prohibiting
race, sex, age, religion, national origin, handicap, disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices, and any claim relating to compensation or benefits. It is
understood and agreed that the waiver of benefits and claims contained in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive or a beneficiary of the Executive may be entitled
under the terms and provisions of any employee benefit plan of the company which have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration to which the Executive may be entitled
under this Agreement or any of the agreements contemplated by this Agreement (including the indemnification agreement and the stock option agreement). The Executive acknowledges that she is entitled to only the severance benefits and compensation
set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby waived, except those expressly stated in the preceding sentence.

 

The Executive hereby acknowledges her understanding that under this Agreement she is
releasing any known or unknown claims she may have.
  

The Executive expressly waives and relinquishes all rights and benefits under that section
and any law of any jurisdiction of similar effect with respect to her release of claims.
  
 The
Executive expressly acknowledged that she has had the opportunity to obtain independent legal advice with respect to the contents, terms and effect of the agreement between myself and the Company including this release and that she fully understands
its content. The consideration described aforesaid is accepted voluntarily for the purpose of making a full, final and irrevocable settlement of all claims described above and The Executive signs this release on her own free will.

 
 

  

 

  
 
EXHIBIT D

 

EXISTING CONFLICTS

 

NIL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]